Mediar Therapeutics

Mediar Therapeutics company information, Employees & Contact Information

Updated June 2026

Quick answer

Mediar Therapeutics is a Biotechnology Research company and founded in 2019. It has approximately 52 employees on record. Contact data was last refreshed in June 2026. Find Mediar Therapeutics's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Mediar Therapeutics is pioneering a new approach to fibrosis treatment that aims to halt the disease at a different source – the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure. Mediar was founded based on a deep understanding of the complex science underlying fibrosis progression. By combining novel targets with reliable, easily detectable blood biomarkers and familiar modalities, Mediar’s goal is to bring forward novel anti-fibrotic therapies that potentially have a precision medicine approach. For more information, contact info@mediartx.com

Company Details

Employees
52
Founded
2019
Address
20 Overland St,
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Boston, Massachusetts
Looking for a particular Mediar Therapeutics employee's phone or email?

Mediar Therapeutics Questions

News

Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial of MTX-463 for Idiopathic Pulmonary Fibrosis - PR Newswire

Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial of MTX-463 for Idiopathic Pulmonary Fibrosis PR Newswire

Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) - PR Newswire

Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) PR Newswire

Mediar Therapeutics Initiates Second Clinical Program in Portfolio of Novel First-In-Class Antibodies Designed to Halt Fibrosis - PR Newswire

Mediar Therapeutics Initiates Second Clinical Program in Portfolio of Novel First-In-Class Antibodies Designed to Halt Fibrosis PR Newswire

Mediar Therapeutics Announces Clinical Candidates for Lead Fibrosis Programs, Strategic Collaborations and Key Leadership Addition - PR Newswire

Mediar Therapeutics Announces Clinical Candidates for Lead Fibrosis Programs, Strategic Collaborations and Key Leadership Addition PR Newswire

Mediar Advances First-in-Class Fibrosis Portfolio to the Clinic with First Cohort Dosing in Phase 1 trial of MTX-463 and Establishes Clinical Advisory Board - PR Newswire

Mediar Advances First-in-Class Fibrosis Portfolio to the Clinic with First Cohort Dosing in Phase 1 trial of MTX-463 and Establishes Clinical Advisory Board PR Newswire

Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies - PR Newswire

Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies PR Newswire

Top Mediar Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant